ACTIVARTIS BIOTECH GMBH

Activartis is developing a novel proprietary cancer immune therapy concept, AV0113, based on Dendritic Cells (DC), which utilises a critically improved methodology for DC manufacturing.

At the beginning of 2013, Activartis competed the recruitment of about 100 brain cancer patients into a randomised phase II clinical trial. An encouraging early trend suggests prolonged overall survival of patients receiving cancer immune therapy compared to control patients.

 

ACTIVARTIS IN THE MODICELL PROJECT

Activartis will deliver immunological data from the analysis of peripheral blood and tumour tissue resident leukocytes derived from patients undergoing cancer immune therapy.

From the detailed clinical investigations of patients participating in the clinical study a correlation of the in silico, in vitro, and in vivo description of the anti-tumour immune status of cancer patients will be possible. 

 

PEOPLE INVOLVED

 

 Thomas Felzmann    Rene Reitermaier  
Thomas Felzmann    Rene Reitermaier    Carmen Visus

strategic and conceptual planning

 

 

biotechnologist, in vitro immune monitoring

 

 

in vitro immune monitoring

 

         
Lioba Lobmayr        

project management

 

     

 

 

 

Project Title: MODICELL

Project No.: 285875

Coordinator: Andreas Heitger

Start: 01/01/2013

Duration: 48 months

Contact: office@modicell.eu

CORDIS: Project Details


LEGAL DETAILS & CONTACT

The Project recieves funding from the European Union FP7-People Programme under grant agreement n° 285875

© MODICELL 2013, Webdesign by BIOLUTION